Page 76 - 2019_04-Haematologica-web
P. 76
M. Kenealy et al.
Most CMML cases (5/7, 71%) had a normal SNP-A karyotype. Rates of SNP-A karyotypic complexity and del(5q) were highest in RAEB-2 (7/16, 43%) and AML (2/4, 50%). Both AML cases with an abnormal karyotype also had deletion of 17p. There were no significant differ- ences between the AZA and AZA+LEN groups in terms of high-risk molecular profile, SNP-A complexity or cytoge- netic risk group. Clinical benefit was most frequent in the
normal SNP-A (29/39, 82%) and IPPS-Rsnp good cytoge- netic risk group (28/39, 82%) cases.
Treatment
With a close out date of 12th March 2016, median follow up was 33.1 months (range 0.7-59.5). There was excellent drug delivery, with the median number of azacitidine cycles per patient administered of 11 in both arms with
Figure 1. Rates of Grade 3+ Anemia (Hb less than 80g/L) baseline and on treatment, rates of Grade 3+ neutrope- nia (reduction neutrophils to less than 50% baseline) and rates of Grade 3+ thrombocytopenia (reduction in platelets to less than 50% baseline).
704
haematologica | 2019; 104(4)
